Role of arachidonic acid metabolism in intervertebral disc degeneration: identification of potential biomarkers and therapeutic targets via multi-omics analysis and artificial intelligence strategies.
Source check: Source checked. Not independent scientific confirmation.
Finding: LASSO, random forest and SVM-RFE feature selection on intervertebral-disc RNA-seq data identified arachidonic-acid-related hub genes, with single-cell and bulk-data analyses supporting disease-stage associations; these are candidate biomarkers, not causal proof. The reviewed source supports this bounded result; external generalization, causal effects, and sustained operational impact remain unestablished where the source reports retrospective or internal evaluation.
Technology: The full text identifies the learned operation and reports its use in the case-specific result.
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
- AI contribution
- The full text identifies the learned operation and reports its use in the case-specific result.
- Test and result
- The original Results text was examined for the reported finding, cohort and analysis scope.
- Limitation / still unknown
- The reported validation/comparison and its limits were checked; interpretation is restricted to the design and cohort described in reason.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://doi.org/10.1186/s12944-023-01962-5 · https://europepmc.org/article/MED/38007425 · https://europepmc.org/articles/PMC10675942 · https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_json/PMC10675942/unicode
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.